drugset / Trial / NCT04933825
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
Unknown
18 enrolled
EdiGene (GuangZhou) Inc.
The First Affiliated Hospital of Henan University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
Timeline
- Start
- 2021-07-20
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ET-02 | Unknown | — | Other |